Metastatic Breast Cancer
‘Disappointing’ data confirm aspirin does not reduce risk for breast cancer relapse
Daily aspirin use did not reduce disease recurrence, progression or mortality in patients with high-risk breast cancer, according to extended follow-up results of a terminated study published in JAMA.
Futibatinib-fulvestrant combination active in FGFR1-amplified advanced breast cancer
SAN ANTONIO — Futibatinib plus fulvestrant exhibited antitumor activity among certain patients with locally advanced or metastatic breast cancer with fibroblast growth factor receptor 1 amplification, according to study results.
Treatment landscape for metastatic breast cancer no longer in a ‘primitive place’
The treatment landscape for metastatic breast cancer has evolved tremendously within the past 2 decades.
Chemotherapy-free regimen induces ‘high’ clinical benefit rate in metastatic breast cancer
SAN ANTONIO — A four-therapy combination conferred clinical benefit to nearly all evaluable patients with metastatic triple-positive breast cancer, according to findings of the ASPIRE trial presented at San Antonio Breast Cancer Symposium.
Exercise program improves quality of life for patients with metastatic breast cancer
SAN ANTONIO — Patients with metastatic breast cancer who take part in a supervised, structured exercise program during palliative treatment may experience improved quality of life, according to study results.
Tinengotinib exhibits activity in pretreated breast cancer
SAN ANTONIO — Tinengotinib exhibited activity among heavily pretreated patients with hormone receptor-positive, HER2-negative breast cancer or those with triple-negative disease, according to study results.
Researcher says to find a mentor who brings you into ‘the room’ where ideas flow
Sarah L. Sammons, MD, was 7 when her mother was diagnosed with breast cancer.
University of Utah professor receives outstanding investigator award
Alana L. Welm, PhD, will receive the AACR Outstanding Investigator Award for Breast Cancer Research during this year’s San Antonio Breast Cancer Symposium.
Tucatinib regimen extends PFS in advanced HER2-positive breast cancer
The addition of tucatinib to ado-trastuzumab emtansine significantly improved PFS among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to study findings.
‘Multiplicity of agents’ saturate treatment landscape for de novo metastatic breast cancer
Significant advancements have been made in the de novo metastatic breast cancer space, including novel agents targeting the HER2 protein and others that enhance anti-estrogen therapies.